WuXi Biologics, headquartered in Shanghai, China, is a global CRDMO providing end-to-end large molecule biologics development and manufacturing services from discovery through commercial production. Established in 2010 as a division of WuXi AppTec and subsequently incorporated in 2015 as an independent entity, the company operates multiple facilities across Asia, Europe, and the U.S. WuXi Biologics offers comprehensive services that include cell line development, analytical testing, pDNA and mRNA manufacturing, LNP formulation, CMC and regulatory support, and GMP drug substance and drug product production, supporting clients in developing innovative biologics and mRNA therapeutics worldwide.
